The present invention generally relates to a transcatheter anti embolic filter, in particular to an intra-aortic filter to be used to protect cerebral and peripheral vessels from potential dissemination of emboli.
The clinical complications related to the implant of a transcatheter heart valve prosthesis (TAVI) are mainly related to the fact that it overlaps the diseased native valve. The heavy presence of tissue calcifications, involving the valve apparatus and the surrounding tissues, influences the correct deployment of the prosthesis creating the conditions for embolic episodes.
The procedural embolic events, so called “macro-embolic cerebral events”, are occurring during a TAVI implant procedure (during predilation, implant or postdilation) and are mainly related to the embolization of macro debris of calcium of fibroelatic particles usually targeting the brain (strokes), the coronary arteries or the peripheral organs. However, the strokes are the most frightful clinical events occurring, nowadays, at a rate of 2.7% against a rate of 3.3% of the previous generations of TAVIs. This reduction of strokes is related to the minor need of pre- and postdilation during TAVI implant nevertheless this data are unclear since are referring to aortic valves with a mild level of calcification. The post-procedural micro-embolic cerebral events are documented in at least 8% of the patients submitted to investigation. The high incidence of new cerebral lesions after TAVI warrants for a longer-term evaluation of neurocognitive function.
In this study conducted over a short-term follow-up period of 3 months, no impairment of neurocognitive function was observed clinically, and the majority of lesions (80%) had resolved on 3-months MRI. However, the issue of periprocedural brain embolization and its potential effects on neurocognitive function may portend greater clinical implications once the indication for TAVI is broadened to include younger patients with long life expectancy.
Future research in the field of TAVI should thus be directed at developing strategies to reduce the risk of embolization (e.g., less traumatic, smaller-bore catheter systems, improved identification of patients at risk for embolization and a potential use of cerebral protection devices).
In some clinical studies at least 10% of the patients, submitted to TAVI implant, show a neurological damage detectable during psychometric tests. While this occurrence rate can be acceptable in high risk and an old patient population it appears unacceptable in lower-risk younger patients. Several clinical studies are ongoing to better investigate this clinical condition.
Another kind of embolic events are the sub-acute and chronic microembolic events occurring after the immediate post-procedural time. The native aortic calcific valve is rough, with a warty surface, immobilized acting like an atherosclerotic ulcerated plaque. This condition is favoring the formation of microtrombi that later-on embolize towards the brain and other peripheral organs. The native aortic valve left in place as a source of microemboli has been taken into account in several clinical studies that demonstrated their role in the onset of vascular origin dementia. This evidence creates a concern when the TAVI are implanted in younger patients where an acceleration of the vascular dementia could impact in a serious way on the social costs.
In summary the periprocedural clinical complications following a TAVI implant are strongly related to the presence of the heavily calcified aortic valve left in place. It brings, acutely, an occurrence of macro-embolic cerebral events (strokes) and hemodynamic consequences such as the PVLs resulting in a various severity of aortic valve insufficiency. These unsatisfactory clinical outcomes are closely related to an irregular deployment of the transcatheter valve prostheses in concomitance of highly calcified aortic native valves.
The longer-term clinical complications are characterized by the cerebral micro-embolizations generated by the native aortic valve leaflets' left in place that become a source of emboli responsible for vascular dementia.
The overall rate of clinical complications in TAVI is ranging between 5% and 12%. This occurrence is most probably underestimated because it does not include patients with highly calcified and biscuspid native valves.
These evidences highlight the importance of protecting the peripheral organs, in particular the brain and the heart, against embolizations occurring during TAVIs procedures.
The increasing overall use of TAVI respect to SAVR, and the higher rate of intermediate risk patients implanted with TAVI, both are indicating the convenience of adopting embolic protection to optimize the long-term survival and quality of life of these patients.
AKI (Acute Kidney Injury) is a frequent complication after TAVI being reported in ranges from 8.3% to 58%. Differing results might partially be explained by the use of different definitions of AKI. In general, this complication is correlated to comorbidities, access route (transfemoral, transapical or others) and amount of contrast liquid used during the procedure. There aren't clinical study on the correlation between the embolization process that occurs during the TAVI procedure and AKI, due also to the absence of a device that can capture the emboli direct to the renal zone, but it's possible to think that the cloud of embolization detached from the valve during the procedure can help the occurrence of this complication.
The abovementioned complications associated to TAVI procedures apply also to other transcatheter procedures, such as valvuloplasty (when unassociated to TAVI), native valve repair and heart recovery procedures, all conditions potentially leading to emboli release from ventricle, native valve or thoracic aorta. Furthermore, catheter navigation itself along a calcified aorta, can make calcification dislodgement and emboli release.
Furthermore, emboli complications are shown in transcatheter procedures other than intra-aortic ones, therefore an antiembolic protection can be highly recommended also for other districts.
Actually, patents applications disclosing emboli protection have been filed since a long time, see for instance U.S. Pat. No. 6,361,545 that shows a perfusion filter catheter able to be adopted in the frame of SAVR and cardiopulmonary bypass procedures or Australian patent application AU 2011202667 that discloses and embolic filter apparatus and method for heart valve replacement.
Nowadays, there are only few devices in clinical use that protect cerebral and peripheral circulation on the frame of transcatheter cardiac and aortic procedures.
The deflector devices deflect emboli from the brachiocephalic trunk and the left common carotid artery towards the peripheral circulation: therefore, they only impede debris entering in the cerebral vessels and diverting them to the peripheral circulation. Moreover, in case of dislodgement from their intended position, the diverting function is missed.
The antiembolic filter on the market, whose main characteristics are disclosed in US Patent Application US 2018/177582, actually captures emboli with a mesh, but only cover two of the three cerebral vessels and not the peripheral circulation.
Other Patents, as US Patent Applications US 2014/0005540 and US 2016/0235515 disclose an embolic protection device filter which is able to protect the cerebral and systemic circulation, although they show some difficulties on the interaction with other working catheters, such as the ones bearing TAVI devices, that need to be positioned before the filter deployments; moreover, during the TAVI positioning, being its catheter outside the filter protection, a small area of the aorta results unprotected; finally, in case TAVI repositioning in descending aorta is required, it would be needed to temporary remove the filter protection.
US Patent Application US 2018/0110607 discloses an embolic protection device filter which is able to protect the cerebral and systemic circulation; the device has a collection chamber for emboli captured containment, and allows the passage of other catheters inside its cylindrical body. Some disadvantages are shown by the mesh pore size, whose range is defined in the range of about 1 mm to about 0.1 mm, and by the absence of a distal closure mechanism that inherently would prevent upstream release of emboli at closure.
International patent application WO 2017/042808 discloses an embolic protection device including a distal porous deflector covering cerebral vessels connected to a proximal emboli collector comprising at least one filter pocket able to be crossed. Although the distal deflector can appear advantageous in terms of encumbrance respect to a full filter configuration, it actually shows disadvantages when interacting with other working catheters, which can result in a loss of cerebral protection in case of small deflector movements.
International patent applications WO 2015/185870 and WO 2018/211344 both disclose a filter device, including a temporary valve prosthesis, designed to be inserted in aorta. Both devices provide improvements with respect to other prior art devices. They however show some drawbacks, such as their positioning proximal respect to the native valve, that limits the possibility to directly operate onto it, and the difficulty to insert additional devices through the prosthesis due to catheter dimensional constraints.
The occurrence of clinical events, as discussed in the previous chapter, are prevented with the device of the present invention, as defined in the claims.
The device according to the invention includes an antiembolic filter comprising a proximal funnel that allows working catheters crossing a generally closed filter port, whilst preventing downstream collected emboli release; this allows the working catheters of accessories and/or transcatheter devices be tracked inside the filter without directly contacting the vessel after, contributing to prevent vessel wall injuries and relevant calcification detachment, whilst preventing emboli release. In addition, the filter has a distal closure mechanism, to be used prior to retrieve the device preventing upstream emboli release at closure. Furthermore, protection of cerebral and peripheral circulation is guaranteed both for macroemboli and microemboli, thanks to adequate filter mesh pore selection.
Preferably, the device according to the invention comprises a transcatheter intraprocedural filter prosthesis for blood vessel (in particular aorta vessel) that includes a tubular filter, expandable distal and proximal support structures; said tubular filter forming a tubular shape when deployed, with a distal end being normally open and a proximal port normally closed. The complete collapsing and deployment of the filter is enabled by the relative linear movement of an external shaft with respect to an internal support catheter.
In a specific intra-aortic embodiment, the distal end of the deployed filter is positioned in ascending aorta, upstream respect to innominate artery, and the proximal end is positioned in descending aorta, downstream respect to the end of aortic arch.
In another specific embodiment, the funnel configuration can be modified during the procedure by maintaining its apex downstream or reverted inside the filter main body or in an intermediate position.
The device can be completely or partially collapsed during the procedure in order to be re-positioned. At the end of the procedure both the distal and proximal closure mechanisms are activated, then the device is collapsed, retracted inside the shaft and fully retrieved out from the patient.
The filter device is intended to be inserted prior to start other transcatheter procedures and to be retrieved after other transcatheter devices removal.
In summary, the filter device here described is adapted to guarantee an antiembolic protection ensuring navigation of other working catheters into the filter, permanent closure at the proximal end and closure at the distal end before filter retrieve, thus giving advantages respect to existing devices and methods.
The invention will be better understood below, in association with some illustrated examples.
1 transcatheter filter device
2 tubular filter
3 main body of the tubular filter
4 funnel
5 distal end of the tubular filter
6 proximal end of the tubular filter
7 port of the tubular filter (coincident with the funnel apex)
8 structure assembly
9 distal structure
10 proximal structure
11 supporting catheter
12 filter-structure-catheter assembly
13 external shaft
14 proximal closure system
15 distal closure system
16 handle and relevant commands, which can comprise the following elements:
17 tip
18 artificial valve
19 radiopaque markers
20 Aortic valve
21 Coronary ostia
22 Sinu Tubular Junction
23 Ascending aorta
24 Innominate artery
25 Aortic arch
26 Descending aorta
27 Femoral access
28 Introducer
29 Guidewire
30 Pigtail
31 Working catheter
32 Funnel lower stitching line
33 Funnel upper stitching line
34 Intermediate structure (example A)
35 Intermediate structure (example B)
In one embodiment, the antiembolic filter device comprises the following macro elements (
The tubular filter 2 is placed externally to the structure assembly 8, as shown in
In specific embodiments (
The tubular filter 2 is preferably made of a low friction porous and flexible polymeric or composite material, here including polyester or polyamide, with mesh pore preferably lower than 150 microns. It can be coated with either a hydrophilic, low friction or anti-thrombogenic coating or a combination of thereof. Filter material, coating and shape facilitate the navigation of transcatheter devices into its body, both during the insertion and the retrieval, preventing relevant direct contact with the vessel wall, that can make injuries on it. Specific embodiments comprise perforated membranes and fabrics. In one embodiment a woven fabric can be chosen, with warp and weft either made by multifilament or monofilament yarn, with an either constant or variable weaving pattern, thus resulting in a pore comprised amongst the square and the circular geometry and either constant or variable mesh pore and open area along the filter longitudinal and circumferential directions.
The tubular filter 2 is geometrically defined by a distal element and a proximal element, namely a main body 3 and a funnel 4 (
Embodiments for the filter main body 3 (
Embodiments for the funnel 4 include movable and fixed funnels, with either symmetric or asymmetric shapes.
A second embodiment for the funnel (
In a third embodiment for the funnel (
The funnel element is generally positioned in a straight portion of the vessel, in order to ensure easy crossing of working catheters at its apex. The funnel is shorter than main body, with a ratio of the funnel to main body length is generally comprised between 1/10 and 1/3, depending on the specific vessel centerline length, shape and vessel diameter. Specific intra-aortic embodiments have a funnel length generally comprised between 2 and 10 cm.
The proximal closure system 14 preventing downstream emboli release, which is positioned at the funnel 4 apex is referred as the filter proximal port 7: it can either consists of a funnel geometry shaped in order to have the apex oriented downstream respect to the blood flow or consists of a folded top or a combination of thereof systems or consists of an actual closure system; an example of closure system is constructed by a lazoo system activated by a wire, either manually 14b or automatically 14a, thanks to an elastic wire.
The distal closure system 15, used to prevent upstream dislodgement at the end of the procedure, is activated before recollapsing the device (
A specific embodiment of the support structure assembly 8 is shown in
The radial expandable characteristics of the distal structure ensure to cover a broad range of geometry (with ascending aorta diameter usually ranging between 20 and 40 mm) and anatomies with a reduced number of sizes for the filter device without risk of device dislodgment or migration.
In the specific embodiment shown in
The distal ring element is designed to radially expand conforming to the aorta in the active configuration, thus guaranteeing a leak-free coupling: this is ensured by the high elasticity limit of the material used, preferably but not exclusively being Nitinol, by its geometry, with perimeter larger than the aorta vessel, by relevant axis free orientation, tilted respect to aorta centerline and by relevant deformation mechanisms commanded by the handle. As an example, by actively pushing on the sealing handle command (forward movement on the command 16b:
In the embodiment shown in
A specific embodiment of the proximal structure 10 is shown in
Specific embodiments can be constructed wherein structures intermediate respect to the distal 9 and proximal 10 can be connected to the supporting catheter 11, in order to increase the device stability and contribute to fully expand the tubular filter main body.
For both the distal and proximal, and where applicable intermediate, structures, the overall geometry can be elliptical in plan view, but also differently shaped as shown in
The supporting catheter 11, which is joined to the distal 9 and proximal 10 structures and to the tubular filter 2, adapts in the active configuration at the extrados of the aortic arch and sustains all the loads arising from the procedure (see
The external shaft 13, see details in
A tip 17 can be included in any of the said structures 9, 11 or external shaft 13 or other structures to allow adequate priming, easy crossing of the introducer and smooth navigation into the aorta (
Radiopaque markers 19, see details in
The handle 16 (
Here below a transcatheter procedure adopting the antiembolic filter device 1 is detailed, with specific features referring to an intra-aortic procedure, here comprising a TAVI, which allow cerebral and systemic emboli protection.
In this example, the antiembolic filter device 1 access is made from the femoral artery opposite (secondary) to that one (main) accessed by the working catheter 31 used for the prosthesis or the device to treat the aortic valve (
Specific procedures can require partial closure, repositioning and re-deployment at different levels (e.g. from sinotubular junction to descending aorta) and, eventually, different supporting catheter positioning.
Moreover, procedures different respect to intra-aortic ones can require different geometrical arrangements of the above-mentioned concepts, therefore this filter device can be applied in principle in any arterial or venous system requiring an antiembolic protection.
This method allows to deploy the filter device prior to the other working catheters 31, see
In another embodiment (
In the embodiment of
Number | Date | Country | Kind |
---|---|---|---|
19167599.0 | Apr 2019 | EP | regional |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2020/059601 | 4/3/2020 | WO | 00 |